MX2007003506A - Terapia de combinacion de cancer que comprende azd2171 e imatinib. - Google Patents
Terapia de combinacion de cancer que comprende azd2171 e imatinib.Info
- Publication number
- MX2007003506A MX2007003506A MX2007003506A MX2007003506A MX2007003506A MX 2007003506 A MX2007003506 A MX 2007003506A MX 2007003506 A MX2007003506 A MX 2007003506A MX 2007003506 A MX2007003506 A MX 2007003506A MX 2007003506 A MX2007003506 A MX 2007003506A
- Authority
- MX
- Mexico
- Prior art keywords
- azd2171
- imatinib
- human
- combination therapy
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se relaciona a un metodo para la produccion de un efecto que reduce la permeabilidad antiangiogenica y/o vascular en un animal de sangre caliente, tal como un ser humano, el cual esta siendo tratado opcionalmente con radiacion ionizante, particularmente un metodo para el tratamiento de cancer, particularmente un cancer que implica un tumor solido o una leucemia, el cual comprende la administracion de AZD2171 en combinacion imatinib; a una composicion farmaceutica que comprende AZD2171 e imatinib; a un producto de combinacion que comprende AZD2171 e imatinib para el uso en un metodo de tratamiento de un cuerpo humano o animal por terapia; a un equipo que comprende AZD2171 e imatinib; al uso de AZD2171 e imatinib en la fabricacion de un medicamento para uso en la produccion de un efecto que reduce la permeabilidad antiangiogenica y/o vascular en un animal de sangre caliente tal como un ser humano el cual esta siendo opcionalmente tratado con radiacion ionizante.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0421436A GB0421436D0 (en) | 2004-09-27 | 2004-09-27 | Combination therapy |
| GB0506725A GB0506725D0 (en) | 2005-04-01 | 2005-04-01 | Combination therapy |
| PCT/GB2005/003672 WO2006035203A1 (en) | 2004-09-27 | 2005-09-23 | Cancer combination therapy comprising azd2171 and imatinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007003506A true MX2007003506A (es) | 2007-05-10 |
Family
ID=35355143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007003506A MX2007003506A (es) | 2004-09-27 | 2005-09-23 | Terapia de combinacion de cancer que comprende azd2171 e imatinib. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20080015205A1 (es) |
| EP (1) | EP1796672A1 (es) |
| JP (1) | JP2008514576A (es) |
| KR (1) | KR20070073813A (es) |
| AU (1) | AU2005288736B2 (es) |
| BR (1) | BRPI0516024A (es) |
| CA (1) | CA2579067A1 (es) |
| IL (1) | IL181608A0 (es) |
| MX (1) | MX2007003506A (es) |
| NO (1) | NO20071426L (es) |
| WO (1) | WO2006035203A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| EP1740170A2 (en) * | 2004-03-23 | 2007-01-10 | AstraZeneca AB | Combination therapy with azd2171 and platinum anti-tumour agent |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| MX2007003505A (es) * | 2004-09-27 | 2007-05-10 | Astrazeneca Ab | Combinacion que comprende zd6474 e imatinib. |
| JP2009500384A (ja) * | 2005-07-06 | 2009-01-08 | アストラゼネカ アクチボラグ | 併用療法 |
| AU2006328201B2 (en) * | 2005-12-22 | 2010-08-19 | Astrazeneca Ab | Combination of AZD2171 and pemetrexed |
| MX2013011199A (es) * | 2011-04-01 | 2013-12-16 | Threshold Pharmaceuticals Inc | Metodos para tratar el cancer. |
| KR101386697B1 (ko) * | 2012-06-18 | 2014-04-18 | 아주대학교산학협력단 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| KR102277833B1 (ko) | 2013-02-20 | 2021-07-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물 및 그의 용도 |
| AU2014296032A1 (en) | 2013-07-31 | 2016-03-17 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| MX355330B (es) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapeuticos y sus usos. |
| WO2015069489A1 (en) | 2013-11-06 | 2015-05-14 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
| AU2017221268B2 (en) * | 2016-02-15 | 2024-02-15 | Astrazeneca Ab | Methods comprising fixed intermittent dosing of cediranib |
| AU2017324251A1 (en) | 2016-09-08 | 2019-03-21 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100838617B1 (ko) * | 1999-02-10 | 2008-06-16 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
| JP2004043390A (ja) * | 2002-07-12 | 2004-02-12 | Nagoya Industrial Science Research Inst | 抗腫瘍剤 |
| EA013811B1 (ru) * | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
| GB2398565A (en) * | 2003-02-18 | 2004-08-25 | Cipla Ltd | Imatinib preparation and salts |
| KR20060097000A (ko) * | 2003-09-23 | 2006-09-13 | 노파르티스 아게 | 화학요법제와 ｖｅｇｆ 수용체 저해제의 배합물 |
-
2005
- 2005-09-23 JP JP2007532962A patent/JP2008514576A/ja active Pending
- 2005-09-23 MX MX2007003506A patent/MX2007003506A/es not_active Application Discontinuation
- 2005-09-23 US US11/663,912 patent/US20080015205A1/en not_active Abandoned
- 2005-09-23 KR KR1020077009368A patent/KR20070073813A/ko not_active Application Discontinuation
- 2005-09-23 BR BRPI0516024-3A patent/BRPI0516024A/pt not_active IP Right Cessation
- 2005-09-23 WO PCT/GB2005/003672 patent/WO2006035203A1/en active Application Filing
- 2005-09-23 CA CA002579067A patent/CA2579067A1/en not_active Abandoned
- 2005-09-23 AU AU2005288736A patent/AU2005288736B2/en not_active Ceased
- 2005-09-23 EP EP05786039A patent/EP1796672A1/en not_active Withdrawn
-
2007
- 2007-02-27 IL IL181608A patent/IL181608A0/en unknown
- 2007-03-16 NO NO20071426A patent/NO20071426L/no not_active Application Discontinuation
-
2009
- 2009-03-23 US US12/408,833 patent/US20090325977A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005288736A1 (en) | 2006-04-06 |
| NO20071426L (no) | 2007-06-18 |
| IL181608A0 (en) | 2007-07-04 |
| KR20070073813A (ko) | 2007-07-10 |
| BRPI0516024A (pt) | 2008-08-19 |
| WO2006035203A1 (en) | 2006-04-06 |
| EP1796672A1 (en) | 2007-06-20 |
| AU2005288736B2 (en) | 2008-08-14 |
| JP2008514576A (ja) | 2008-05-08 |
| US20090325977A1 (en) | 2009-12-31 |
| US20080015205A1 (en) | 2008-01-17 |
| CA2579067A1 (en) | 2006-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
| HK1123186A1 (en) | Combination of zd6474 and pemetrexed zd6474 | |
| HK1123976A1 (en) | Combination of azd2171 and pemetrexed azd2171 | |
| HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
| ZA200600188B (en) | Combination therapy | |
| WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent | |
| IL177953A0 (en) | Combination therapy including azd2171 and a taxane | |
| WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |